TNF-α is produced in high concentrations in chronic inflammatory disease, resulting in excessive inflammation which eventually leads to organ damage. The advent of anti-TNF therapy in clinical practice 20 years ago represented a significant change in the management of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), axial spondylarthritis (SpA), psoriasis, and inflammatory bowel disease (IBD).

What lies in wait for pharma in the social media jungle?

T2D remission (an HbA1c <48 mmol/mol without the use of glucose lowering medications for 6 months), improvements in cardiovascular risk factors, and decreased T2D-associated mortality can be achieved through sustained weight loss.

CoMiSSTM is a clinical tool developed to increase awareness among healthcare professionals (HCP) of possible symptoms of cow’s milk allergy (CMA) in infants. During this symposium, leading experts in the field of paediatric gastroenterology, allergy, and nutrition highlighted how CoMiSS can facilitate awareness of CMA and support HCPs in improving the patient journey from symptom presentation to diagnosis.

Blockchain allow patients to own their data and better protects their personal information. How could it change the data landscape in pharma?